Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Cut to Hold at Berenberg Bank

Berenberg Bank cut shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) from a buy rating to a hold rating in a research report report published on Tuesday, Marketbeat reports.

A number of other brokerages have also recently issued reports on FMS. Sanford C. Bernstein lifted their target price on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Truist Financial set a $25.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, August 5th. Zacks Research raised shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Weiss Ratings reissued a “hold (c)” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research note on Tuesday, August 4th. Finally, BNP Paribas Exane downgraded Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective for the company. in a research report on Tuesday, July 28th. Seven analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Reduce” and a consensus target price of $23.67.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.6%

Shares of FMS stock opened at $22.24 on Tuesday. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $27.64. The stock has a market cap of $11.94 billion, a P/E ratio of 11.52, a P/E/G ratio of 4.07 and a beta of 0.74. The business has a fifty day simple moving average of $23.33 and a 200-day simple moving average of $22.94. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.43.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a return on equity of 9.28% and a net margin of 4.83%.The business had revenue of $5.55 billion during the quarter, compared to the consensus estimate of $5.48 billion. On average, analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP boosted its stake in shares of Fresenius Medical Care AG & Co. KGaA by 31.5% during the 2nd quarter. Allworth Financial LP now owns 3,552 shares of the company’s stock worth $80,000 after purchasing an additional 850 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA in the second quarter valued at approximately $91,000. EverSource Wealth Advisors LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 50.3% in the first quarter. EverSource Wealth Advisors LLC now owns 4,135 shares of the company’s stock valued at $93,000 after buying an additional 1,383 shares during the last quarter. Parallel Advisors LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 27.9% in the first quarter. Parallel Advisors LLC now owns 4,632 shares of the company’s stock valued at $104,000 after buying an additional 1,011 shares during the last quarter. Finally, Kathmere Capital Management LLC purchased a new position in shares of Fresenius Medical Care AG & Co. KGaA during the first quarter valued at approximately $219,000. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney disease and kidney failure. The company provides dialysis care through a global network of outpatient clinics and supports patients with related medical services, including vascular access care, laboratory services and care coordination.

In addition to operating dialysis facilities, Fresenius Medical Care develops and manufactures products used in dialysis treatment.